Investor Relations

Latest News

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023

Mineralys Therapeutics to Participate in Three Upcoming Conferences

Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Event icon

Coporate Presentation

Mineralys Corporate Overview December 2023

Presentation icon

Latest Event

Evercore ISI 6th Annual HealthCONx Conference

Latest Financial Results

Q3 2023

Quarter Ended Sep 30, 2023

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Company Overview

Mineralys Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company committed to developing treatments for diseases that are driven by abnormally elevated aldosterone. The Company’s clinical-stage product candidate, lorundrostat, is a highly selective aldosterone synthase inhibitor, licensed from Mitsubishi Tanabe Pharma Corporation (“Mitsubishi Tanabe”), that is being investigated for the treatment of hypertension. The Company has completed a Phase 2 proof-of-concept study in patients with uncontrolled hypertension and has plans for the continued research and development of lorundrostat in hypertension and other potential indications. The Company was incorporated as a Delaware corporation in May 2019, and it is headquartered in Radnor, Pennsylvania.

Stock Snapshot

Contact Information


Mineralys Therapeutics, Inc.
150 N. Radnor Chester Rd
Suite F200
Radnor, PA 19087
United States
Toll-Free: 888-378-6240

Transfer Agent

American Stock Transfer & Trust Company LLC
6201 15th Avenue
Brooklyn, New York 11219
United States
T: 800-937-5449
F: 718-236-2641


Elixir Health Public Relations
Tom Weible
T: 515-707-9678

Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.